Press Releases Archives - Page 34 of 103 - Lupin

BSE 2442.35 NSE 2442.90

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2442.35 NSE 2442.90

Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®

February 9, 2022

Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution15 mcg (base)/2 ml

February 8, 2022

Lupin Quarter 3 FY2022 Results

February 3, 2022

Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa

February 1, 2022

Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

January 27, 2022

Lupin Signs First Partnership Agreement with Foncoo for China

January 19, 2022

Lupin launches Molnupiravir under the brand name Molnulup for the treatment of COVID-19 in adults in India

January 7, 2022

Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension

December 25, 2021

Lupin Receives Tentative Approval from U.S. FDA for Azilsartan Medoxomil Tablets

December 24, 2021

Lupin’s Goa Manufacturing Plant Receives EIR from US FDA

December 14, 2021

1 2 … 33 34 35 … 102 103

Search

Hit enter to search or ESC to close